Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01226004
Other study ID # FRRA01
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 2010
Est. completion date July 2020

Study information

Verified date August 2019
Source Florida Robotic Radiosurgery Association
Contact Mark L Perman, MD
Phone 772-403-2390
Email permanmark@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To address pertinent questions regarding the utilization of stereotactic Body Radiotherapy (SBRT) to treat prostate cancer. The Florida Robotic Radiosurgery Association (FRRA) launched the first registry for prostate cancer patients treated with SBRT. The registry is designed to track surrogate treatment endpoints including prostate specific antigen (PSA), international prostate symptom score (IPSS),sexual health in men (SHIM), and visual analogue scale (VAS) scores, in addition to physical and survival data. Utilizing an independent vendor (Advertek, Inc.) experienced with the design and implementation of similar electronic registries, FRRA developed a data collection tool that staff members with a basic medical background can use to register and upload pertinent patient data, requiring no more than 20 to 30 minutes per patient. Participating patients will be monitored in follow-up for three years, with analysis and publication of the results semi-annually.


Description:

To address pertinent questions regarding the utilization of radiosurgery (SBRT) to treat prostate cancer. The Florida Robotic Radiosurgery Association (FRRA) launched the first registry for prostate cancer patients treated with SBRT.

The registry is designed to track surrogate treatment endpoints including PSA, IPSS, SHIM, QOL, Karnofsky Performance Status, VAS scores, urine and bowel health, in addition to physical and survival data. Utilizing an independent vendor (Advertek, Inc.) experienced with the design and implementation of similar electronic registries.

FRRA developed a data collection tool that staff members with a basic medical background can use to register and upload pertinent patient data requiring no more than 20 to 30 minutes per patient. Participating patients will be monitored in follow-up for three years, with analysis and publication of the results semi-annually.


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date July 2020
Est. primary completion date July 2020
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- pathological diagnosis of prostate cancer

- early or intermediate risk

Exclusion Criteria:

- high risk prostate cancer

Study Design


Related Conditions & MeSH terms

  • Prostate Cancer Early Risk Treated by Radiosurgery
  • Prostate Cancer Intermediate Risk Treated by Radiosurgery
  • Prostatic Neoplasms

Locations

Country Name City State
United States Austin CyberKnife Austin Texas
United States Saint Vincent Frontier Cancer Center Billings Montana
United States CyberKnife of Birmingham Birmingham Alabama
United States Penrose Cancer Center Colorado Springs Colorado
United States Premier Cancer Centers Dallas Texas
United States CyberKnife Center of Chicago Elmhurst Illinois
United States Inova Fairfax Hospital Falls Church Virginia
United States The Center for Cancer and Blood Disorders Fort Worth Texas
United States California Cancer Care Fresno California
United States Benefis Sletten Cancer Institute Great Falls Montana
United States Philadelphia CyberKnife Havertown Pennsylvania
United States Las Vegas CyberKnife Henderson Nevada
United States St. Luke's Medical Center Houston Texas
United States St. Mary's Medical Center Huntington West Virginia
United States United Health Services Johnson City New York
United States First Dayton Cancer Care Kettering Ohio
United States Colorado CyberKnife Lafayette Colorado
United States Baptist Health Lexington Kentucky
United States St. Elizabeth CyberKnife Center Lincoln Nebraska
United States Anova Cancer Care Lone Tree Colorado
United States WellStar Research Insititute Marietta Georgia
United States CyberKnife Center of Miami Miami Florida
United States Montana Cancer Institute Foundation Missoula Montana
United States University of South Alabama-USA Mitchell Cancer Institute Mobile Alabama
United States Naples Radiation Oncology Naples Florida
United States Sarah Cannon Cancer Center Nashville Tennessee
United States Newport Diagnostic Center Newport Beach California
United States Illinois Cyberknife Park Ridge Illinois
United States Memorial Cancer Institute CyberKnife Center Pembroke Pines Florida
United States Phoenix CyberKnife & Radiation Oncology Center Phoenix Arizona
United States Riverview Medical Center Red Bank New Jersey
United States Reno CyberKnife Reno Nevada
United States The START Center for Cancer Care San Antonio Texas
United States Scripps Clinic Radiation Therapy Centers San Diego California
United States Spokane CyberKnife Spokane Valley Washington
United States CyberKnife Center of South Florida in Stuart Stuart Florida
United States CyberKnife Centers of Tampa Bay Tampa Florida
United States Cancer Treatment Centers of America Tulsa Oklahoma
United States Oklahoma CyberKnife Tulsa Oklahoma
United States St. John Medical Center Tulsa Oklahoma
United States Skyline Radiation Oncology Tustin California
United States Cyberknife of Texas at East Texas Medical Center Tyler Texas
United States PeaceHealth Southwest Medical Center Vancouver Washington
United States Georgetown University Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Florida Robotic Radiosurgery Association

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival 5 years
Secondary Treatment Outcomes Measurement of surrogate outcomes including IPSS and SHIM scores 5 years
Secondary Treatment toxicity urinary and rectal complications as well as sexual health 5 years
Secondary Assess biochemical disease free survival using PSA 5 years